- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04232774
Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities (NECTAR)
Study Overview
Status
Intervention / Treatment
Detailed Description
Diabetes mellitus is among the most prevalent chronic diseases, affecting 435 million persons as of 2015 with an annual death toll of 1.5 million, and the overwhelming majority of these have Type 2 diabetes mellitus (T2DM). Hypertension is a common comorbidity of diabetes and present in more than 50% of diabetic patients. The risk for cardiovascular disease (CVD) is four-fold higher in patients with both DM and hypertension as compared to the normotensive non-diabetic controls. Obesity, with a prevalence of over 500 million, is another common comorbidity of diabetes. These are chronic diseases associated with increased risks of cardiovascular disease, stroke, and decreased quality of life.
Neurotronic developed a novel catheter for denervation procedure. Chemical agent is delivered locally into the adventitial space and ablates the sympathetic nerve and nerve endings in the adventitial space of the target arteries.
The purpose of the study is to assess the safety and feasibility of chemical denervation of the target arteries for the treatment of Type 2 diabetes (T2DM) and its comorbidities.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yunlong Zhang
- Phone Number: 669-203-9308
- Email: pzhang@libramed.com
Study Contact Backup
- Name: John Chen
- Phone Number: 763-273-6100
- Email: chenj@neurotronic.com
Study Locations
-
-
-
Asunción, Paraguay
- Sanatorio Italiano - Centro de Intervenciones Endovasculares
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 22 and ≤ 70 years at time of enrollment.
Diagnosed with uncontrolled T2DM with baseline.
- Fasting plasma glucose ≥ 155 mg/dl (8.6 mmol/l)
- HbA1c levels ≥ 7.5% and < 10% (58-86 mmol/mol)]
- On oral anti-hyperglycemic drug regimen of at least two different drug classes, and one of the two being metformin ≥ 1500 mg/day
- History of positive response to metformin dosage escalation, i.e., HbA1c reduction of 0.5% or more
- Diagnosed hypertension with baseline office blood pressure of SBP of ≥ 150 mmHg and ≤ 180 mmHg and DBP ≥ 90 mmHg.
- BMI between 27.5 and 45 kg/m2 and weight < 400lbs.
- Vessel diameter of 3 mm to 7 mm with a minimum arterial treatable length of 20 mm.
Exclusion Criteria:
- T1DM or poorly controlled T2DM (defined as HbA1c >10.0%).
- Hypoglycemia unawareness or serious hypoglycemia with loss of consciousness or confusion sufficient to prevent self-treatment in last 6 months;
- Diagnosed proliferative retinopathy or evidence of peripheral neuropathy.
- Lack of appropriate treatment site or anatomy precluding the intervention of the target arteries.
- History of prior target artery intervention including balloon angioplasty, stenting, etc.
- Arterial stenosis >50% of the normal diameter segment (diameter stenosis, compared to the angiographically normal proximal or distal segment).
- Any abnormality or disease in one or more of the target arteries that, per the physician assessment, precludes the safe insertion of the guiding catheter (including, but not limited to, artery aneurysm, excessive tortuosity, artery calcification)
- Known or suspected secondary hypertension, such as Cushing's disease or Cushing's Syndrome, hyperaldosteronism, pheochromocytoma, thyroid and parathyroid abnormalities, history of pre-eclampsia, onset of hypertension prior to the age of 18.
- Use of nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment.
- Severe or unstable cardiovascular comorbidities, such as AMI or ACS, cardiac valve stenosis, pulmonary embolism, heart failure with NYHA Class III or IV, chronic atrial fibrillation, primary pulmonary hypertension, COPD.
- Renal transplant, history of nephrectomy or single kidney, renal tumor/cancer, known non-functioning kidney, unequal renal size (>2 cm difference in renal length between kidneys associated with a chronic kidney disease or a deterioration of the kidney function), chronic renal deficiency with eGFR ≤60ml/min/1.73m2, or on chronic renal replacement therapy.
- Liver transplant.
- Gastrointestinal permanent anatomic alteration surgery
- Bleeding disorders, such as bleeding diathesis, thrombocytopenia, and severe anemia.
- Systemic infection that the investigator judges would pose unacceptable procedural risks to the subject.
- Known hypersensitivity to contrast media, nickel and the chemical agent that cannot be adequately pre-medicated.
- Occlusive peripheral vascular disease that would preclude percutaneous femoral access for the procedure.
- Subject is depressed or on antidepressants.
- Pregnancy or breastfeeding or plan to get pregnant in next 12 months.
- Life expectancy of less than 12 months.
- Unwilling or unable to comply with the follow-up study requirements.
- Lacking capacity to provide informed consent.
- Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety.
- Currently participation in another pre-market drug or medical device clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treated by the study device
|
a sterile, single use catheter (device) for delivering chemical agent to achieve perivascular denervation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Serious Device- and Procedure-Related Complications
Time Frame: at 30 Days post procedure
|
This composite endpoint is defined as:
|
at 30 Days post procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycemic Control (1)
Time Frame: at baseline and at post-procedure: 2-week, 1-month, 3-month, 6-month, 12-month and 24-month follow-up visits. Also, optionally at 3-,4- and 5-year post-procedure follow-up visits.
|
Improvement of HbA1c (%) will be analyzed by absolute and relative changes.
Percent subjects with decrease HbA1c will also be analyzed.
|
at baseline and at post-procedure: 2-week, 1-month, 3-month, 6-month, 12-month and 24-month follow-up visits. Also, optionally at 3-,4- and 5-year post-procedure follow-up visits.
|
Glycemic Control (2)
Time Frame: at baseline and at post-procedure: 2-week, 1-month, 3-month, 6-month, 12-month and 24-month follow-up visits. Also, optionally at 3-,4- and 5-year post-procedure follow-up visits.
|
Improvement of fasting glucose (mg/dl) will be analyzed by absolute and relative changes.
Percent subjects with decrease fasting glucose will also be analyzed.
|
at baseline and at post-procedure: 2-week, 1-month, 3-month, 6-month, 12-month and 24-month follow-up visits. Also, optionally at 3-,4- and 5-year post-procedure follow-up visits.
|
Hypertension Control
Time Frame: at baseline and at post-procedure: 2-week, 1-month, 3-month, 6-month, 12-month and 24-month follow-up visits. Also, optionally at 3-,4- and 5-year post-procedure follow-up visits.
|
Improvement of blood pressure (mmHg) will be analyzed by absolute and relative changes.
|
at baseline and at post-procedure: 2-week, 1-month, 3-month, 6-month, 12-month and 24-month follow-up visits. Also, optionally at 3-,4- and 5-year post-procedure follow-up visits.
|
Weight Control (1)
Time Frame: at baseline and at post-procedure: 2-week, 1-month, 3-month, 6-month, 12-month and 24-month follow-up visits. Also, optionally at 3-,4- and 5-year post-procedure follow-up visits.
|
The improvement of the body weight (weight in kg) will be analyzed by absolute and relative changes.
|
at baseline and at post-procedure: 2-week, 1-month, 3-month, 6-month, 12-month and 24-month follow-up visits. Also, optionally at 3-,4- and 5-year post-procedure follow-up visits.
|
Weight Control (2)
Time Frame: at baseline and at post-procedure: 2-week, 1-month, 3-month, 6-month, 12-month and 24-month follow-up visits. Also, optionally at 3-,4- and 5-year post-procedure follow-up visits.
|
The improvement of the body weight will be analyzed by Body Mass Index (BMI in kg/m^2) absolute and relative changes.
|
at baseline and at post-procedure: 2-week, 1-month, 3-month, 6-month, 12-month and 24-month follow-up visits. Also, optionally at 3-,4- and 5-year post-procedure follow-up visits.
|
Device Success
Time Frame: during procedure or immediately after procedure
|
Device success, defined as successful introduction of the catheter, navigation to the treatment site, deployment of the features, and infusion of the chemical agent to the intended area without device malfunction that requiring abort the procedure.
|
during procedure or immediately after procedure
|
Procedure Success
Time Frame: during procedure or immediately after procedure
|
Procedure success, defined as device success without any serious device- and procedure-related complications during the procedure and prior to hospital discharge.
|
during procedure or immediately after procedure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: John Chen, Neurotronic, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR 2010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus With Circulatory Complciation
-
Bota Bio Co., Ltd.CompletedType 2 Diabetes Mellitus With Circulatory Complciation
-
RenJi HospitalRuijin HospitalCompletedType 2 Diabetes Mellitus With Circulatory ComplciationChina
-
Peking Union Medical College HospitalChinese Academy of Sciences; The First Affiliated Hospital of Zhengzhou University and other collaboratorsNot yet recruitingEfficacy and Safety of Bifidobacterium Quadruple Live Tablets in Patients With T2DM and ConstipationType 2 Diabetes Mellitus With ComplicationChina
-
George E. DafoulasUniversity of Ioannina; Centre for Research and Technology HellasRecruitingDiabetes Mellitus Type 2 With HypoglycemiaGreece
-
Heidelberg Engineering GmbHCompletedNormal Eyes of Subjects Without Diabetes Mellitus | Subjects With Diabetes Mellitus Type 2 Without Coexisting DPN | Subjects With Diabetes Mellitus Type 2 With Coexisting Early to Moderate DPN
-
University of LincolnCompletedDiabetes Mellitus Type 2 With HypoglycemiaJordan
-
AstraZenecaCompletedAdult Patients With Type 2 Diabetes MellitusKorea, Republic of
-
University of HullCompletedType 2 Diabetes Mellitus With HypoglycemiaUnited Kingdom
-
Seoul National University HospitalCompletedType 2 Diabetes Mellitus With HypoglycemiaKorea, Republic of
-
Solvay PharmaceuticalsCompleted
Clinical Trials on The Neurotronic arterial ablation catheter
-
Rigshospitalet, DenmarkUnknown
-
Sequoia HospitalUnknownPersistent Atrial Fibrillation | Chronic Atrial FibrillationUnited States
-
University of California, San FranciscoMedtronicCompleted
-
Hangzhou Broncus Medical Co., Ltd.CompletedLung Neoplasms | Pulmonary MetastasisChina
-
Hangzhou Broncus Medical Co., Ltd.Shanghai Chest HospitalRecruitingStage IA Lung CancerChina
-
Neurotronic, Inc.Libra MedicalRecruitingHypertension | Diabetes Mellitus, Type 2Panama, Paraguay
-
Charles University, Czech RepublicRecruitingAtrial FibrillationCzechia
-
University of CalgaryCompletedAtrial FibrillationCanada
-
Dartmouth-Hitchcock Medical CenterCompletedShock | Renal Failure | Hypotension | Mechanical Ventilation Complication | Bloodstream Infection | Arterial Thrombosis | Limb Ischemia | Vasopressor Adverse ReactionUnited States
-
Oxford University Hospitals NHS TrustRoyal Bournemouth and Christchurch Hospitals NHS Foundation TrustCompleted